dermconsult

Host: Raj Chovatiya, MD, PhD
Guest: George Han, MD, PhD

Our understanding of TYK2’s role in the pathophysiology of psoriasis has recently evolved, leading to new treatment options like deucravacitinib. Deucravacitinib is the first approved TYK2 inhibitor approved for moderate to severe plaque psoriasis. Learn more about this treatment option and the role of TYK2 with Dr. Raj Chovatiya and Dr. George Han, Associate Professor in the Department of Dermatology at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell in Uniondale, New York.

Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Jonathan Silverberg, MD, PhD, MPH

Atopic dermatitis is more than a disease of the skin. It’s a complex and heterogeneous inflammatory disease mediated by multiple T-cell–driven inflammatory pathways, like the OX40 pathway, leading to chronic and persistent symptoms and significant burden.^1-4 Explore the heterogeneity of atopic dermatitis and the importance of OX40 signaling in disease pathogenesis with Dr Charles Turck and Dr. Jonathan Silverberg, Professor and Director of Clinical Research and the Director of Patch Testing at George Washington University School of Medicine and Health Sciences.

References:

1. Silverberg JI. Clinical Management of Atopic Dermatitis. 1st ed. 2018.
2. Ratchataswan T, et al. J Allergy Clin Immunol Pract. 2021;9:1053-1065.
3. Weidinger S, et al. Nat Rev Dis Primers. 2018;4:1.
4. De Bruyn Carlier T, et al. J Autoimmun. 2021;120:102634.

©2023 Amgen Inc. All rights reserved. USA-451-80031 8/23

Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Jonathan Silverberg, MD, PhD, MPH

Atopic dermatitis is more than a disease of the skin. It’s a complex and heterogeneous inflammatory disease mediated by multiple T-cell–driven inflammatory pathways, like the OX40 pathway, leading to chronic and persistent symptoms and significant burden.^1-4 Explore the heterogeneity of atopic dermatitis and the importance of OX40 signaling in disease pathogenesis with Dr Charles Turck and Dr. Jonathan Silverberg, Professor and Director of Clinical Research and the Director of Patch Testing at George Washington University School of Medicine and Health Sciences.

References:

1. Silverberg JI. Clinical Management of Atopic Dermatitis. 1st ed. 2018.
2. Ratchataswan T, et al. J Allergy Clin Immunol Pract. 2021;9:1053-1065.
3. Weidinger S, et al. Nat Rev Dis Primers. 2018;4:1.
4. De Bruyn Carlier T, et al. J Autoimmun. 2021;120:102634.

©2023 Amgen Inc. All rights reserved. USA-451-80031 8/23

Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Jonathan Silverberg, MD, PhD, MPH

Atopic dermatitis is more than a disease of the skin. It’s a complex and heterogeneous inflammatory disease mediated by multiple T-cell–driven inflammatory pathways, like the OX40 pathway, leading to chronic and persistent symptoms and significant burden.^1-4 Explore the heterogeneity of atopic dermatitis and the importance of OX40 signaling in disease pathogenesis with Dr Charles Turck and Dr. Jonathan Silverberg, Professor and Director of Clinical Research and the Director of Patch Testing at George Washington University School of Medicine and Health Sciences.

References:

1. Silverberg JI. Clinical Management of Atopic Dermatitis. 1st ed. 2018.
2. Ratchataswan T, et al. J Allergy Clin Immunol Pract. 2021;9:1053-1065.
3. Weidinger S, et al. Nat Rev Dis Primers. 2018;4:1.
4. De Bruyn Carlier T, et al. J Autoimmun. 2021;120:102634.

©2023 Amgen Inc. All rights reserved. USA-451-80031 8/23

Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Jonathan Silverberg, MD, PhD, MPH

Atopic dermatitis is more than a disease of the skin. It’s a complex and heterogeneous inflammatory disease mediated by multiple T-cell–driven inflammatory pathways, like the OX40 pathway, leading to chronic and persistent symptoms and significant burden.^1-4 Explore the heterogeneity of atopic dermatitis and the importance of OX40 signaling in disease pathogenesis with Dr Charles Turck and Dr. Jonathan Silverberg, Professor and Director of Clinical Research and the Director of Patch Testing at George Washington University School of Medicine and Health Sciences.

References:

1. Silverberg JI. Clinical Management of Atopic Dermatitis. 1st ed. 2018.
2. Ratchataswan T, et al. J Allergy Clin Immunol Pract. 2021;9:1053-1065.
3. Weidinger S, et al. Nat Rev Dis Primers. 2018;4:1.
4. De Bruyn Carlier T, et al. J Autoimmun. 2021;120:102634.

©2023 Amgen Inc. All rights reserved. USA-451-80031 8/23

Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Jonathan Silverberg, MD, PhD, MPH

Atopic dermatitis is more than a disease of the skin. It’s a complex and heterogeneous inflammatory disease mediated by multiple T-cell–driven inflammatory pathways, like the OX40 pathway, leading to chronic and persistent symptoms and significant burden.^1-4 Explore the heterogeneity of atopic dermatitis and the importance of OX40 signaling in disease pathogenesis with Dr Charles Turck and Dr. Jonathan Silverberg, Professor and Director of Clinical Research and the Director of Patch Testing at George Washington University School of Medicine and Health Sciences.

References:

1. Silverberg JI. Clinical Management of Atopic Dermatitis. 1st ed. 2018.
2. Ratchataswan T, et al. J Allergy Clin Immunol Pract. 2021;9:1053-1065.
3. Weidinger S, et al. Nat Rev Dis Primers. 2018;4:1.
4. De Bruyn Carlier T, et al. J Autoimmun. 2021;120:102634.

©2023 Amgen Inc. All rights reserved. USA-451-80031 8/23

Host: Raj Chovatiya, MD, PhD
Guest: Jason E. Hawkes, MD, MS, FAAD

Generalized pustular psoriasis is a rare inflammatory skin disease that can be life-threatening if left untreated, and treatment typically involves the use of therapies approved for plaque psoriasis. However, that could all be changing thanks to the recent understanding of IL-36’s role in generalized pustular psoriasis and the development of the treatment option spesolimab. Learn more with Dr. Raj Chovatiya and Dr. Jason Hawkes, medical dermatologist in the Greater Sacramento area who also sits on the National Psoriasis Foundation Medical Board and Scientific Advisory Committee.

Host: Raj Chovatiya, MD, PhD
Guest: Jason E. Hawkes, MD, MS, FAAD

Generalized pustular psoriasis is a rare inflammatory skin disease that can be life-threatening if left untreated, and treatment typically involves the use of therapies approved for plaque psoriasis. However, that could all be changing thanks to the recent understanding of IL-36’s role in generalized pustular psoriasis and the development of the treatment option spesolimab. Learn more with Dr. Raj Chovatiya and Dr. Jason Hawkes, medical dermatologist in the Greater Sacramento area who also sits on the National Psoriasis Foundation Medical Board and Scientific Advisory Committee.

Host: Raj Chovatiya, MD, PhD
Guest: Jason E. Hawkes, MD, MS, FAAD

Roflumilast and tapinarof are two of the new topical nonsteroidal therapies for plaque psoriasis that have several advantages over the traditional topical steroids. Learn more about how emerging topical nonsteroidals could impact your patients with plaque psoriasis with Dr. Raj Chovatiya and Dr. Jason Hawkes, a medical dermatologist in the Greater Sacramento area who also sits on the National Psoriasis Foundation Medical Board and Scientific Advisory Committee.

Host: Raj Chovatiya, MD, PhD
Guest: Jason E. Hawkes, MD, MS, FAAD

Roflumilast and tapinarof are two of the new topical nonsteroidal therapies for plaque psoriasis that have several advantages over the traditional topical steroids. Learn more about how emerging topical nonsteroidals could impact your patients with plaque psoriasis with Dr. Raj Chovatiya and Dr. Jason Hawkes, a medical dermatologist in the Greater Sacramento area who also sits on the National Psoriasis Foundation Medical Board and Scientific Advisory Committee.

Host: Jason J. Luke, MD, FACP
Guest: Tara C. Mitchell, MD

The 5-year recurrence rates for stage IIB and IIC melanoma are up to 46%, but now new immunotherapy options are FDA-approved for the adjuvant treatment of stage IIB and IIC melanoma. Find out why this matters and hear Drs. Jason Luke and Tara Mitchell break down the latest data on treating stage IIB and IIC melanoma with adjuvant immunotherapy.

Host: Jason J. Luke, MD, FACP
Guest: Tara C. Mitchell, MD

The 5-year recurrence rates for stage IIB and IIC melanoma are up to 46%, but now new immunotherapy options are FDA-approved for the adjuvant treatment of stage IIB and IIC melanoma. Find out why this matters and hear Drs. Jason Luke and Tara Mitchell break down the latest data on treating stage IIB and IIC melanoma with adjuvant immunotherapy.

Host: Jason J. Luke, MD, FACP
Guest: Tara C. Mitchell, MD

The 5-year recurrence rates for stage IIB and IIC melanoma are up to 46%, but now new immunotherapy options are FDA-approved for the adjuvant treatment of stage IIB and IIC melanoma. Find out why this matters and hear Drs. Jason Luke and Tara Mitchell break down the latest data on treating stage IIB and IIC melanoma with adjuvant immunotherapy.

Host: Jason J. Luke, MD, FACP
Guest: Tara C. Mitchell, MD

The 5-year recurrence rates for stage IIB and IIC melanoma are up to 46%, but now new immunotherapy options are FDA-approved for the adjuvant treatment of stage IIB and IIC melanoma. Find out why this matters and hear Drs. Jason Luke and Tara Mitchell break down the latest data on treating stage IIB and IIC melanoma with adjuvant immunotherapy.

Host: Jason J. Luke, MD, FACP
Guest: Tara C. Mitchell, MD

The 5-year recurrence rates for stage IIB and IIC melanoma are up to 46%, but now new immunotherapy options are FDA-approved for the adjuvant treatment of stage IIB and IIC melanoma. Find out why this matters and hear Drs. Jason Luke and Tara Mitchell break down the latest data on treating stage IIB and IIC melanoma with adjuvant immunotherapy.

Host: Jason J. Luke, MD, FACP
Guest: Tara C. Mitchell, MD

The 5-year recurrence rates for stage IIB and IIC melanoma are up to 46%, but now new immunotherapy options are FDA-approved for the adjuvant treatment of stage IIB and IIC melanoma. Find out why this matters and hear Drs. Jason Luke and Tara Mitchell break down the latest data on treating stage IIB and IIC melanoma with adjuvant immunotherapy.

Host: Jason J. Luke, MD, FACP
Guest: Tara C. Mitchell, MD

The 5-year recurrence rates for stage IIB and IIC melanoma are up to 46%, but now new immunotherapy options are FDA-approved for the adjuvant treatment of stage IIB and IIC melanoma. Find out why this matters and hear Drs. Jason Luke and Tara Mitchell break down the latest data on treating stage IIB and IIC melanoma with adjuvant immunotherapy.

Host: Jason J. Luke, MD, FACP
Guest: Tara C. Mitchell, MD

The 5-year recurrence rates for stage IIB and IIC melanoma are up to 46%, but now new immunotherapy options are FDA-approved for the adjuvant treatment of stage IIB and IIC melanoma. Find out why this matters and hear Drs. Jason Luke and Tara Mitchell break down the latest data on treating stage IIB and IIC melanoma with adjuvant immunotherapy.

CME credits: 0.25
Valid until: 09-06-2024
Claim your CME credit at https://reachmd.com/programs/cme/preventing-disease-recurrence-adjuvant-therapy-stage-iibiic-melanoma/15392/

The 5-year recurrence rates for stage IIB and IIC melanoma are up to 46%, but now new immunotherapy options are FDA-approved for the adjuvant treatment of stage IIB and IIC melanoma. Find out why this matters and hear Drs. Jason Luke and Tara Mitchell break down the latest data on treating stage IIB and IIC melanoma with adjuvant immunotherapy.

=

Host: Jason J. Luke, MD, FACP
Guest: Tara C. Mitchell, MD

The 5-year recurrence rates for stage IIB and IIC melanoma are up to 46%, but now new immunotherapy options are FDA-approved for the adjuvant treatment of stage IIB and IIC melanoma. Find out why this matters and hear Drs. Jason Luke and Tara Mitchell break down the latest data on treating stage IIB and IIC melanoma with adjuvant immunotherapy.